Coeptis Therapeutics initiated with a Buy at Ladenburg

Ladenburg initiated coverage of Coeptis Therapeutics with a Buy rating and $3 price target. Coeptis is a cell therapy company with three platform technologies, notes the analyst, who adds that the company’s most recent transaction was the partial acquisition of Deverra Therapeutics, which also has an advanced cell therapy named dilanubicel that is expected to enter Phase 3 clinical trial in de novo acute myeloid leukemia, or AML, patients. The firm considers cell therapy valuations at “depressed levels currently” and thinks Coeptis is well positioned to advance in at least two of its platforms, Deverra or CD38 NK, the analyst tells investors.